Back to Results

Sol Gel Technologies Ltd (SLGL)

Sol-Gel Technologies Ltd. is a healthcare company focused on developing topical dermatology treatments for patients with severe skin conditions. Its commercial products include Twyneo, a once-daily non-antibiotic cream for acne vulgaris, and Epsolay, a once-daily topical cream for papulopustular rosacea. The company is also advancing pipeline candidates, including SGT-610, which is in Phase 3 trials for Gorlin syndrome, and SGT-210, which has completed Phase I testing for olmsted syndrome. Sol-Gel works with Padagis Israel Pharmaceuticals Ltd. and has licensing agreements with Galderma Holding SA and Searchlight Pharma Inc. Founded in 1997, the company is headquartered in Ness Ziona, Israel, and its common stock trades on the NASDAQ under the symbol SLGL.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-SLGL
$48.16
-21.0% Downside
Overvalued
$152.50
150.2% Upside
Bargain
Fair
0.0%
November 5, 2026
4.0x
108.1x
199.6 M
146.9 M
0.4%
14.9%
0.8
52.6%
Valuation • Fair Value

Sol Gel Technologies Ltd (NASDAQ-SLGL) Fair Value by Valuation Model

Review the available estimates for Sol Gel Technologies Ltd (NASDAQ-SLGL), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$48.16

Estimated downside of 21.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$68.26

Discounted cash flow valuation reference.

Comps Fair Value

$41.45

Comparable-company valuation reference.

Analyst Price Target

$152.50

Analysts imply upside of 150.2%.

How to read these valuation models

Use the 5 available valuation references for Sol Gel Technologies Ltd (NASDAQ-SLGL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Sol Gel Technologies Ltd (NASDAQ-SLGL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

1.795 M

Current operating scale indicator.

Revenue Forecast

354 K

Forward revenue estimate.

EBITDA

-17.69 M

Current operating profitability reference.

EBITDA Forecast

-23.9 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Sol Gel Technologies Ltd (NASDAQ-SLGL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Sol Gel Technologies Ltd (NASDAQ-SLGL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-5.85

No elevated caution signal from this screen.

Altman Z-Score

0.8

Lower score that deserves closer risk review.

FCF / Net Income

52.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Sol Gel Technologies Ltd (NASDAQ-SLGL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Sol Gel Technologies Ltd (NASDAQ-SLGL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

44

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Sol Gel Technologies Ltd (NASDAQ-SLGL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Sol Gel Technologies Ltd (NASDAQ-SLGL) Stock Forecast & Technical Outlook

Review Sol Gel Technologies Ltd (NASDAQ-SLGL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Sol Gel Technologies Ltd (NASDAQ-SLGL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Sol Gel Technologies Ltd (NASDAQ-SLGL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Sol Gel Technologies Ltd (NASDAQ-SLGL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Sol Gel Technologies Ltd (NASDAQ-SLGL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Sol Gel Technologies Ltd (NASDAQ-SLGL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Sol Gel Technologies Ltd (NASDAQ-SLGL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Sol Gel Technologies Ltd (NASDAQ-SLGL) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Sol Gel Technologies Ltd (NASDAQ-SLGL) Stock FAQ

Data-supported answers about Sol Gel Technologies Ltd (NASDAQ-SLGL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$48.16
Estimated downside 21.0%
Valuation Rating
Overvalued
Estimated downside of 21.0%
Analyst Target
$152.50
Implied upside 150.2%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Sol Gel Technologies Ltd (NASDAQ-SLGL) is $48.16. This implies an estimated downside of 21.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 21.0% versus the current market price.

The available analyst price target for Sol Gel Technologies Ltd (NASDAQ-SLGL) is $152.50. The analyst target implies estimated upside of 150.2%.

The current financial health read for Sol Gel Technologies Ltd (NASDAQ-SLGL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Sol Gel Technologies Ltd (NASDAQ-SLGL) is November 5, 2026.

The latest available data indicates no current dividend yield for Sol Gel Technologies Ltd (NASDAQ-SLGL).

The current market capitalization listed for Sol Gel Technologies Ltd is 199.6 M.

The current enterprise value listed for Sol Gel Technologies Ltd is 146.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Sol Gel Technologies Ltd is NASDAQ-SLGL, and the stock is listed on NASDAQ.

Sol Gel Technologies Ltd (NASDAQ-SLGL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Sol Gel Technologies Ltd is 0.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Sol Gel Technologies Ltd is 14.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B